Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...

Efforts to find an easy, early COVID-19 treatment may ... can’t emerge because the drug makes too many other damaging mutations,” Denison says. Merck says it can make as many as 10 million ...

New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.